Announcements Trials
Browse Landscape

Phase

Phase 2 23Phase 3 18Phase 1 10Phase 2/3 5Phase 1/2 4

Status

Recruiting 3Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 2Pancreatic Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Locally Advanced Pancreatic Cancer 1Colorectal Neoplasms 1Anal Cancer Metastatic 1

Interventions

pembrolizumab 42Specimen Handling 38Magnetic Resonance Spectroscopy 30Carboplatin 30Cyclophosphamide 27Biopsy 25Nivolumab 23Dexamethasone 22fludarabine 21Gemcitabine 19Bevacizumab 15Paclitaxel 14Temozolomide 13Pemetrexed 13Docetaxel 13Cisplatin 13atezolizumab 12Ipilimumab 12Rituximab 11venetoclax 10Prednisone 10Lenalidomide 9Injections 9Fulvestrant 9lenvatinib 8X-Rays 8Vincristine 8Trastuzumab 8Oxaliplatin 8Fluorouracil 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × 130-nm albumin-bound paclitaxel × 30 days × Clear all
NCT07223047 2026-05-28

A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies

Bristol-Myers Squibb

Phase 1/2 Recruiting
252 enrolled
GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT05431270 2026-05-19

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

Phanes Therapeutics

Phase 1/2 Recruiting
40 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT07280377 2026-05-19

GOBLET

Oncolytics Biotech

Phase 1/2 Active not recruiting
122 enrolled
Gastrointestinal

Anal Cancer Metastatic

NCT03652428 2026-05-06

Phase I Nab-Paclitaxel Plus Gemcitabine With Proton Therapy for Locally Advanced Pancreatic Cancer (LAPC)

University of Maryland, Baltimore

Phase 1/2 Recruiting
24 enrolled
Gastrointestinal

Locally Advanced Pancreatic Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡